Illumina Inc (ILMN) 172.26 $ILMN
Integra Poised on Impressive Duraseal Product Line, Solid Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:50PM CDT
On Jul 3, 2014, we issued an updated research report on Integra LifeSciences Holdings Corporation (IART).
Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:44AM CDT
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as the company saw its shares rise over 5% on the day.
Illumina Set to Possibly Pullback After Yesterday's Rally of 2.30%
Comtex SmarTrend(R) - Wed Sep 17, 4:20PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $173.21 to a high of $177.10. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $176.93 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.30% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 17, 4:20PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $173.21 to a high of $177.10. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $176.93 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Global Bioinformatics Market Outlook 2019
M2 - Wed Sep 17, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xtd5rk/global) has announced the addition of the "Global Bioinformatics Market Outlook 2019" report to their offering. The global bioinformatics market reached the mark of around US$ 3.7 Billion in 2013 with the anticipation of its growth at a CAGR of around 19% during 2015-2019 The report is an outcome of an in-depth research and comprehensive analysis of global developments and opportunities listed in the section of the bioinformatics trends. The bioinformatics market essentially is divided into 3 sections for a categorical study of the industry viz. by segment, by application and by region. By segment, the bioinformatics market is divided into data analysis and software, tools and database services, and IT Infrastructure. Accordingly, the report provides a comprehensive analysis of each of these segments coupled with the information on key software and databases popular in the industry. In the application area of the bioinformatics industry, the report covers various aspects of the global bioinformatics market, giving detailed analysis of its various applications, including genomics, proteomics, transcriptomics, cheminformatics, metabolomics and molecular phylogenetics, covering the sizes of the bioinformatics market for each of these application areas till 2019. The report also offers a geographical picture of the bioinformatics sector in four regions viz. North America, Europe, Asia-Pacific and Latin America. Additionally, through country level analysis, the report portrays the bioinformatics market in major countries like US, UK, South Korea, India etc., to understand their individual market growth and future directions. A competitive analysis in the report has been done with an assortment of all the major bioinformatics players that have been active in the research and development of bioinformatics products and services. It encloses the overview, key financials and strategic initiatives by the players. In a nutshell, the research provides all the prerequisite information for intending clients looking out to venture into this industry and facilitates them to devise strategies, while going for an investment/partnership in the global bioinformatics market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Key Industry Trends and Drivers 4. Bioinformatics Market Outlook to 2019 5. Country Level Analysis 6. Commercialized Products and Services 7. Key Players - Biodiscovery, Inc. - Geneva Bioinformatics (Genebio) SA - Kinexus Bioinformatics Corporation - Accelrys, Inc. - Affymetrix, Inc. - Agilent Technologies, Inc. - CLC Bio A/S - Genologics Life Sciences Software, Inc - ID Business Solutions Ltd - Illumina Inc. - Life Technologies Corporation - NonLinear Dynamics Ltd. For more information visit http://www.researchandmarkets.com/research/xtd5rk/global
Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:30PM CDT
On Sep 16, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:44AM CDT
Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise over 9% on the day
IBD 50 Names Hold Gains, But Actionable Charts Scarce
at Investor's Business Daily - Mon Sep 15, 1:37PM CDT
Plenty of IBD 50 names are showing resilience and holding near highs. Damaged charts are the exception, not the rule. That's the good news. The bad news is that new buys aren't easy to find for growth investors looking to put new money to work. A...
Does Illumina's Latest Base Have The Profit Gene?
at Investor's Business Daily - Fri Sep 12, 5:20PM CDT
Technology from Illumina (ILMN), a leader in genetic test equipment, has helped bring down the costs of genomic testing in recent years. And it just launched an initiative to develop standardized FDA-approved kits to improve cancer diagnostic and...
After Yesterday's Decline of 2.48%, Illumina Offers Investors Better Value
Comtex SmarTrend(R) - Fri Sep 12, 4:31PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $171.88 to a high of $176.93. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $173.68 on volume of 996,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Illumina Set to Possibly Rebound After Yesterday's Selloff of 2.48%
Comtex SmarTrend(R) - Fri Sep 12, 4:31PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $171.88 to a high of $176.93. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $173.68 on volume of 996,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:44AM CDT
Cytokinetics (CYTK) as a big mover last session, as the company saw its shares surge over 17 % on the day
Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 2:00PM CDT
Myriad Genetics, Inc. (MYGN) reported favorable results from a pivotal clinical utility study of its myPath Melanoma test.
Global Next Generation Sequencing (NGS) Market to 2020 - Platforms, Bioinformatics, Technology & Applications
M2 - Wed Sep 10, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhhxfb/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market by Platforms, Bioinformatics , Technology & by Application - Global Forecast to 2020" report to their offering. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020. The NGS market segments such as pre-sequencing products and services, NGS platforms, sequencing services and data analysis/bioinformatics are rapidly growing markets. The overall NGS market is flourishing by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. Developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions are major opportunities for this market. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. The growth can be attributed to the increasing demand for presequencing consumables and instruments as the quality of the end product depends on the presequencing treatment. The growing need for standardized sample preparation solutions and increasing automation in the pre-sequencing workflow step are drivers of this market. The study is confined to platforms, consumables and services provided by top 4 companies, Illumina, Thermo Fisher (Life Technologies), Roche and Pacific Biosciences. It does not include other NGS platforms and miscellaneous consumables/reagents offered by other companies. Also, market estimation does not consider upcoming technologies or platforms. Scope Platforms - Illumina HiSeq - MiSeq - HiSeqX Ten - NextSeq 500 - Thermo Fisher Ion Proton/PGM Bioinformatics - Exome Sequencing - RNA-Seq - ChIP-Seq Technology - SBS - SMRT Application - Diagnostics - Personalized Medicine Companies Mentioned - 454 Life Sciences Corporation (Roche Holding Ag) - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters, Ltd. - Clc Bio (Acquired By Qiagen) - Dnastar, Inc. - Gatc Biotech Ag - Genomatix Software Gmbh - Illumina, Inc. - Knome, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Macrogen, Inc. - Oxford Nanopore Technologies, Ltd. - Pacific Biosciences - Partek Incorporated - Perkin Elmer, Inc. - Qiagen N.V. For more information visit http://www.researchandmarkets.com/research/dh...generation
Illumina, Inc. (NASDAQ: ILMN) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Sep 09, 9:11AM CDT
What:
Quiet Stocks Are Typical In Market Right Now
at Investor's Business Daily - Mon Sep 08, 5:18PM CDT
Quiet volume has been the chief characteristic of the stock market in recent weeks. The last time either the Nasdaq or the S&P 500 showed above-average volume for the week was in the week ended Aug. 1. Many leaders in the Big Cap 20 are also keeping...
Why Illumina (ILMN) Stock Is Gaining Today
at The Street - Mon Sep 08, 9:56AM CDT
Illumina (ILMN) shares are up after having coverage initiated with an 'equal weight' rating by analysts at Morgan Stanley (MS) on Monday.
Actionable Genome Consortium Forms with Cross Disciplinary Leaders from World-Renowned Cancer Institutions
Business Wire - Mon Sep 08, 5:30AM CDT
--Consortium Will Recommend Standards for Applying Next-Generation Sequencing to Cancer Tumors
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Integra Poised on Impressive Duraseal Product Line, Solid Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:50PM CDT
On Jul 3, 2014, we issued an updated research report on Integra LifeSciences Holdings Corporation (IART).
Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:44AM CDT
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as the company saw its shares rise over 5% on the day.
Illumina Set to Possibly Pullback After Yesterday's Rally of 2.30%
Comtex SmarTrend(R) - Wed Sep 17, 4:20PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $173.21 to a high of $177.10. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $176.93 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.30% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 17, 4:20PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $173.21 to a high of $177.10. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $176.93 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Global Bioinformatics Market Outlook 2019
M2 - Wed Sep 17, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xtd5rk/global) has announced the addition of the "Global Bioinformatics Market Outlook 2019" report to their offering. The global bioinformatics market reached the mark of around US$ 3.7 Billion in 2013 with the anticipation of its growth at a CAGR of around 19% during 2015-2019 The report is an outcome of an in-depth research and comprehensive analysis of global developments and opportunities listed in the section of the bioinformatics trends. The bioinformatics market essentially is divided into 3 sections for a categorical study of the industry viz. by segment, by application and by region. By segment, the bioinformatics market is divided into data analysis and software, tools and database services, and IT Infrastructure. Accordingly, the report provides a comprehensive analysis of each of these segments coupled with the information on key software and databases popular in the industry. In the application area of the bioinformatics industry, the report covers various aspects of the global bioinformatics market, giving detailed analysis of its various applications, including genomics, proteomics, transcriptomics, cheminformatics, metabolomics and molecular phylogenetics, covering the sizes of the bioinformatics market for each of these application areas till 2019. The report also offers a geographical picture of the bioinformatics sector in four regions viz. North America, Europe, Asia-Pacific and Latin America. Additionally, through country level analysis, the report portrays the bioinformatics market in major countries like US, UK, South Korea, India etc., to understand their individual market growth and future directions. A competitive analysis in the report has been done with an assortment of all the major bioinformatics players that have been active in the research and development of bioinformatics products and services. It encloses the overview, key financials and strategic initiatives by the players. In a nutshell, the research provides all the prerequisite information for intending clients looking out to venture into this industry and facilitates them to devise strategies, while going for an investment/partnership in the global bioinformatics market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Key Industry Trends and Drivers 4. Bioinformatics Market Outlook to 2019 5. Country Level Analysis 6. Commercialized Products and Services 7. Key Players - Biodiscovery, Inc. - Geneva Bioinformatics (Genebio) SA - Kinexus Bioinformatics Corporation - Accelrys, Inc. - Affymetrix, Inc. - Agilent Technologies, Inc. - CLC Bio A/S - Genologics Life Sciences Software, Inc - ID Business Solutions Ltd - Illumina Inc. - Life Technologies Corporation - NonLinear Dynamics Ltd. For more information visit http://www.researchandmarkets.com/research/xtd5rk/global
Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:30PM CDT
On Sep 16, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:44AM CDT
Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise over 9% on the day
IBD 50 Names Hold Gains, But Actionable Charts Scarce
at Investor's Business Daily - Mon Sep 15, 1:37PM CDT
Plenty of IBD 50 names are showing resilience and holding near highs. Damaged charts are the exception, not the rule. That's the good news. The bad news is that new buys aren't easy to find for growth investors looking to put new money to work. A...
Does Illumina's Latest Base Have The Profit Gene?
at Investor's Business Daily - Fri Sep 12, 5:20PM CDT
Technology from Illumina (ILMN), a leader in genetic test equipment, has helped bring down the costs of genomic testing in recent years. And it just launched an initiative to develop standardized FDA-approved kits to improve cancer diagnostic and...
After Yesterday's Decline of 2.48%, Illumina Offers Investors Better Value
Comtex SmarTrend(R) - Fri Sep 12, 4:31PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $171.88 to a high of $176.93. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $173.68 on volume of 996,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Illumina Set to Possibly Rebound After Yesterday's Selloff of 2.48%
Comtex SmarTrend(R) - Fri Sep 12, 4:31PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $171.88 to a high of $176.93. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $173.68 on volume of 996,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:44AM CDT
Cytokinetics (CYTK) as a big mover last session, as the company saw its shares surge over 17 % on the day
Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 2:00PM CDT
Myriad Genetics, Inc. (MYGN) reported favorable results from a pivotal clinical utility study of its myPath Melanoma test.
Global Next Generation Sequencing (NGS) Market to 2020 - Platforms, Bioinformatics, Technology & Applications
M2 - Wed Sep 10, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhhxfb/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market by Platforms, Bioinformatics , Technology & by Application - Global Forecast to 2020" report to their offering. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020. The NGS market segments such as pre-sequencing products and services, NGS platforms, sequencing services and data analysis/bioinformatics are rapidly growing markets. The overall NGS market is flourishing by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. Developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions are major opportunities for this market. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. The growth can be attributed to the increasing demand for presequencing consumables and instruments as the quality of the end product depends on the presequencing treatment. The growing need for standardized sample preparation solutions and increasing automation in the pre-sequencing workflow step are drivers of this market. The study is confined to platforms, consumables and services provided by top 4 companies, Illumina, Thermo Fisher (Life Technologies), Roche and Pacific Biosciences. It does not include other NGS platforms and miscellaneous consumables/reagents offered by other companies. Also, market estimation does not consider upcoming technologies or platforms. Scope Platforms - Illumina HiSeq - MiSeq - HiSeqX Ten - NextSeq 500 - Thermo Fisher Ion Proton/PGM Bioinformatics - Exome Sequencing - RNA-Seq - ChIP-Seq Technology - SBS - SMRT Application - Diagnostics - Personalized Medicine Companies Mentioned - 454 Life Sciences Corporation (Roche Holding Ag) - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters, Ltd. - Clc Bio (Acquired By Qiagen) - Dnastar, Inc. - Gatc Biotech Ag - Genomatix Software Gmbh - Illumina, Inc. - Knome, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Macrogen, Inc. - Oxford Nanopore Technologies, Ltd. - Pacific Biosciences - Partek Incorporated - Perkin Elmer, Inc. - Qiagen N.V. For more information visit http://www.researchandmarkets.com/research/dh...generation
Illumina, Inc. (NASDAQ: ILMN) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Sep 09, 9:11AM CDT
What:
Quiet Stocks Are Typical In Market Right Now
at Investor's Business Daily - Mon Sep 08, 5:18PM CDT
Quiet volume has been the chief characteristic of the stock market in recent weeks. The last time either the Nasdaq or the S&P 500 showed above-average volume for the week was in the week ended Aug. 1. Many leaders in the Big Cap 20 are also keeping...
Why Illumina (ILMN) Stock Is Gaining Today
at The Street - Mon Sep 08, 9:56AM CDT
Illumina (ILMN) shares are up after having coverage initiated with an 'equal weight' rating by analysts at Morgan Stanley (MS) on Monday.
Actionable Genome Consortium Forms with Cross Disciplinary Leaders from World-Renowned Cancer Institutions
Business Wire - Mon Sep 08, 5:30AM CDT
--Consortium Will Recommend Standards for Applying Next-Generation Sequencing to Cancer Tumors
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
